Business
Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021
NEWARK, Calif., June 7, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist" or "the Company") today announced that management will
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"NEWARK, Calif., June 7, 2021 /PRNewswire/ -- Protagonist Therapeutics (Nasdaq: PTGX) (\"Protagonist\" or \"the Company\") today announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera (PV), which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress. The conference call will take place on Friday, June 11, 2021, at 8:00 a.m. EDT (14:00 CEST). \nThe call will feature members of the Protagonist management team and Ronald Hoffman, M.D., Albert A. and Vera G. List Professor of Medicine, Hematology and Medical Oncology, and Director of the Myeloproliferative Disorders Research Program at Mount Sinai Hospital, and a lead investigator of the Phase 2 study.\nFeatured Abstract\nRusfertide (PTG-300) Eliminates the Need for Therapeutic Phlebotomy in Both Low and High-Risk Polycythemia Vera (PV) Patients (S200; Kremyanskaya, et al). The oral presentation will be made available on demand to registered meeting attendees at ehaweb.org on Friday, June 11, 2021 at 9:00 CEST.\nConference Call and Webcast Information\nLive audio of the conference call will be simultaneously broadcast over the internet. The call will be available to investors, members of the news media, and the general public.\nTo access the live call, dial (877) 870-4263 (U.S./Canada) or (412) 317-0790 (international) five minutes prior to the call and ask to be joined to the Protagonist Therapeutics call. A live and archived webcast will be accessible in the Investors section of the Company's website at www.protagonist-inc.com.\nAbout Protagonist Therapeutics\nProtagonist Therapeutics is a biopharmaceutical company with multiple peptide-based investigational new chemical entities in different stages of development, all derived from the Company's proprietary technology platform.\nProtagonist's pipeline includes rusfertide (PTG-300), an investigational, injectable hepcidin mimetic currently in a Phase 2 proof-of-concept clinical trial for polycythemia vera (PV), a Phase 2 study in PV subjects with high hematocrit levels, and a Phase 2 study for hereditary hemochromatosis. Based on the feedback provided by the FDA and EU regulatory authorities, the Company plans to initiate a single, glob...